Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Pharmacol Toxicol Methods. 2018 Jun 22;93:46–58. doi: 10.1016/j.vascn.2018.06.006

Table 2.

All cell types and all compounds tested at each participating site.

Compound Cell Type Site
High Risk Disopyramide AXG, CDI, PLR, CLS 1,2,3,4
Quinidine AXG, CDI, PLR, CLS 1,2,3,4
D,l Sotalol AXG, CDI, PLR, CLS 1,2,3,4
Vandetanib AXG, CDI, PLR, CLS 1,2,3,4
Intermediate Risk Astemizole AXG, CDI 1,3
Chlorpromazine AXG, CDI 1
Cisapride AXG, CDI 1
Clarithromycin AXG, CDI 1
Droperidol AXG, CDI, PLR, CLS 2
Domperidone AXG, CDI, PLR, CLS 2
Ondansetron AXG, CDI, CLS 3,4
Pimozide AXG, CDI, PLR, CLS 2,3,4
Risperidone AXG, CDI, CLS 3,4
Terfenadine AXG, CDI, PLR, CLS 2,4
Low risk Diltiazem AXG, CDI, CLS 1,4
Loratadine AXG, CDI, CLS 1,4
Metoprolol AXG, CLS 4
Mexiletine AXG, CDI, CLS 3,4
Nifedipine AXG, CDI, PLR, CLS 2
Nitrendipine AXG, CDI, PLR, CLS 2
Ranolazine AXG, CDI, PLR, CLS 2,3
Tamoxifen AXG, CDI, PLR, CLS 1,2,3
Verapamil AXG, CDI, CLS 1,3

Compounds are grouped by risk of manifesting Human TdP, and are ranked as high, intermediate and low risk.